Abstract |
Oncogenes act as inducers of tumor neovascularization, at least in part through suppression of endogenous angiogenesis inhibitors, e.g., thrombospondin 1 (TSP-1/THSP1). Therefore, restoration of TSP-1 levels can be viewed as a possible means to inhibit tumor angiogenesis. We observed that low concentrations (0.1-10 microg/ml) of doxycycline (but not those of related tetracycline) restore TSP-1 expression in H-ras oncogene-expressing tumor cell lines (528ras1, MT-Ras). Interestingly, this effect was relatively ras-specific, as doxycycline did not alter TSP-1 expression in several cell lines (e.g., 528neu2 fibrosarcoma, B16F1 melanoma, and Lewis lung carcinoma) harbouring other types of transforming alterations. Doxycycline-induced reversal of TSP down-regulation was abrogated under hypoxic conditions. Therefore, we conclude that, in vivo, TSP-1 is likely under dual and/or synergistic control of oncogenes and hypoxia-related pathways. Disruption of both components may be necessary for the 'rescue' of TSP-1 expression in ras-driven cancers.
|
Authors | Wojciech Kalas, Sarah Gilpin, Joanne L Yu, Linda May, Halka Krchnakova, Paul Bornstein, Janusz Rak |
Journal | Biochemical and biophysical research communications
(Biochem Biophys Res Commun)
Vol. 310
Issue 1
Pg. 109-14
(Oct 10 2003)
ISSN: 0006-291X [Print] United States |
PMID | 14511656
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Thrombospondin 1
- Doxycycline
|
Topics |
- Animals
- Dose-Response Relationship, Drug
- Doxycycline
(pharmacology)
- Gene Expression Regulation, Neoplastic
(drug effects)
- Genes, ras
- Mice
- Mutation
- Thrombospondin 1
(metabolism)
- Tumor Cells, Cultured
|